HIPRA

HIPRA is a biotech pharmaceutical company headquartered in Amer, Catalonia, Spain focused on prevention for animal and human health, with a product base of vaccines and diagnostic services.

HIPRA has an international presence in 40 countries with its own subsidiaries, 3 R&D centres and production plants located in Europe (Spain) and America (Brazil).

In addition, its international distribution network maintains open distribution channels with more than 100 countries, covering all 5 continents.

Since 2020, the company has been developing a vaccine against COVID-19.

History
HIPRA got founded in 1971, in a small laboratory in Madrid. The name HIPRA comes from the surnames of its former creators: Hidalgo and Prada.

In 1991 HIPRA had a workforce of 100 people and a turnover of 10 million euros, it was an important year in HIPRA's history, with a new management team, and a redefined company expansion policy.

In the year 2000, the company began internationalization, beginning the implementation of its own subsidiaries around the world. Currently HIPRA has commercial subsidiaries in 40 countries. It also has 3 research centers and 6 production plants located in Europe and America.

In 2009 HIPRA began to focus on prevention; therefore, it stopped investing in pharmacological products.

In 2021 the new Human Health division was created by HIPRA to create new products. The same year, GoodGut was acquired by HIPRA, a biotechnological start-up dedicated to the research and development of diagnostic tests for digestive diseases.

Animal health
HIPRA has developed more than 100 vaccines for different animal species, both production and companion animals, against a wide variety of biological targets. In addition to its Amer plant, the company has another plant in Brazil, in the Porto Alegre conurbation. It also has a university research centre in the United States.

HIPRA's animal health products include vaccines, vaccination devices, integrated traceability services and diagnostic kits.